Simultaneous determination of hydrochlorothiazide and valsartan in human plasma by liquid chromatography/tandem mass spectrometry

Analytical Letters

Volumn 41, Issue 8, 2008, Pages 1348-1365

  Liu, Fei ^a   Zhang, Jundong ^b   Xu, Yu ^a   Gao, Shu ^b   Guo, Qingxiang ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b Hefei Con source Medicine Technology Corporation   (China)

Author keywords

HPLC; Human plasma; Hydrochlorothiazide; Mass spectrometry; Valsartan

Indexed keywords

EID: 47249094090     PISSN: 00032719     EISSN: 1532236X     Source Type: Journal    
DOI: 10.1080/00032710802119186     Document Type: Article

References (22)

1. Carlucci, G., Di Carlo, V., and Mazzeo, P. 2000. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by high-performance liquid chromatography. Anal. Lett., 33 (12): 2491-2500.
2. Crespo, M.J. and De Mello, W.C. 2001. Chronic administration of losartan plus hydrochlorothiazide improves vascular status in young cardiomyopathic hamsters. Eur. J. Pharmacol., 420 (2-3): 133-141.
3. Dinc, E., Uslu, B., and Ozkan, S.A. 2004. Spectral resolution of a binary mixture containing valsartan and hydrochlorothiazide in tablets by ratio spectra derivative and inverse least square techniques. Anal. Lett., 37 (4): 679-693.
4. Erk, N. 2002. Spectrophotometric analysis of valsartan and hydrochlorothiazide. Anal. Lett., 35 (2): 283-302.
5. Huang, T.M., He, Z., Yang, B., Shao, L.P., Zheng, X.W., and Duan, G.L. 2006. Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution. J. Pharm. Biomed. Anal., 41 (2): 644-648.
6. Iriarte, G., Ferreiros, N., Ibarrondo, I., Alonso, R.M., Maguregi, M.I., Gonzalez, L., and Jimenez, R.M. 2006. Optimization via experimental design of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples. J. Sep. Sci., 29 (15): 2265-2283.
7. Kocyigit-Kaymakcoglu, B., Unsalan, S., and Rollas, S. 2006. Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography. Pharmazie, 61 (7): 586-589.
8. Li, H., Wang, Y.W., Jiang, Y., Tang, Y.B., Wang, J., Zhao, L.M., and Gu, J.K. 2007. A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of valsartan and hydrochlorothiazide in human plasma. J. Chromatogr. B, 852 (1-2): 436-442.
9. Macek, J., Klima, J., and Ptacek, P. 2006. Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. J. Chromatogr. B, 832 (1): 169-172.
10. Matuszewski, B.K., Constanzer, M.L., and Chavez-Eng, C.M. 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem., 75 (13): 3019-3030.
11. Miller, R.B. and Amestoy, C. 1992. A liquid-chromatographic method for the determination of hydrochlorothiazide in human plasma. J. Pharm. Biomed. Anal., 10 (7): 541-545.
12. Mistry, N.B., Westheim, A.S., and Kjeldsen, S.E. 2006. The angiotensin receptor antagonist valsartan: A review of the literature with a focus on clinical trials. Expert Opin. Pharmacother., 7 (5): 575-581.
13. Niopas, I. and Daftsios, A.C. 2002. A validated HPLC method for the determination of hydrochlorothiazide in human plasma and its application in pharmacokinetic studies. J. Liq. Chromatogr. Relat. Technol., 25 (3): 487-494.
14. Pool, J.L., Glazer, R., Weinberger, M., Alvarado, R., Huang, J., and Graff, A. 2007. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin. Ther., 29 (1): 61-73.
15. Ramakrishna, N.V.S., Vishwottam, K.N., Manoj, S., Koteshwara, M., Wishu, S., and Varma, D.P. 2005. Sensitive liquid chromatography-tandem mass spectrometry method for quantification of hydrochlorothiazide in human plasma. Biomed. Chromatogr., 19 (10): 751-760.
16. Satana, E., Altinay, S., Goger, N.G., Ozkan, S.A., and Senturk, Z. 2001. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J. Pharm. Biomed. Anal., 25 (5-6): 1009-1013.
17. Tatar, S. and Saglik, S. 2002. Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J. Pharm. Biomed. Anal., 30 (2): 371-375.
18. U.S. Department of Health and Human Services, Food and Drug Administration. 2001, May. Guidance for Industry - Bioanalytical Method Validation.
19. Wagstaff, A.J. 2006. Valsartan/hydrochlorothiazide - A review of its use in the management of hypertension. Drugs, 66 (14): 1881-1901.
20. Wellington, K. and Faulds, D.M. 2002. Valsartan/hydrochlorothiazide - A review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs, 62 (13): 1983-2005.
21. Yang, H.Y., Kao, P.F., Chen, T.H., Tomlinson, B., Ko, W.C., and Chan, P. 2007. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients. J. Clin. Pharmacol., 47 (3): 397-403.
22. Zendelovska, D., Stafilov, T., and Milosevski, P. 2004. Development of solid-phase extraction method and its application for determination of hydrochlorothiazide in human plasma using HPLC. Biomed. Chromatogr., 18 (2): 71-76.